San Diego, CA -- (SBWIRE) -- 09/15/2014 -- An investor, who purchased shares of Marrone Bio Innovations Inc (NASDAQ:MBII), filed a lawsuit in the U.S. District Court for the Eastern District of California over alleged violations of Federal Securities Laws by Marrone Bio Innovations Inc in connection with certain allegedly false and misleading statements made between March 6, 2014 and September 2, 2014.

Investors who purchased shares of Marrone Bio Innovations Inc (NASDAQ:MBII) have certain options and for certain investors are short and strict deadlines running. Deadline: November 4, 2014. NASDAQ:MBII investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of purchasers of Marrone Bio Innovations Inc (NASDAQ:MBII) common shares between March 6, 2014 and September 2, 2014, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that Defendants made allegedly false and/or misleading statements and/or failed to disclose that Marrone Bio Innovations Inc’s financial statements contained errors related to the improper recognition of revenues, that Marrone Bio Innovations Inc lacked adequate internal controls over financial reporting, and that as a result of the foregoing, Marrone Bio Innovations Inc’s financial statements were allegedly materially false and misleading at all relevant times.

Marrone Bio Innovations Inc reported that its annual Total Revenue rose from $7.14 million in 2012 to $14.54 million in 2013 and that its Net Loss declined from $38.79 million in 2012 to $28.49 million in 2013. Shares of Marrone Bio Innovations Inc (NASDAQ:MBII)

On September 3, 2014, Marrone Bio Innovations Inc announced that, at the recommendation of management, the Audit Committee of its Board of Directors has commenced an internal investigation after management learned of documents calling into question the recognition of revenue in the fourth quarter of 2013 for an $870,000 transaction. Marrone Bio Innovations Inc said its Audit Committee has retained independent legal advisers to assist it in this investigation. Additionally, the Audit Committee has determined that the company's financial statements for the fiscal year ended December 31, 2013, the unaudited interim financial statements for the three month period ended March 31, 2014 and the three- and six- month periods ended June 30, 2014, should no longer be relied upon as being in compliance with generally accepted accounting principles.

Shares of Marrone Bio Innovations Inc (NASDAQ:MBII) declined from $18.65 per share in January 2014 to as low as $2.80 per share on September 5, 2014.

On September 11, 2014, NASDAQ:MBII shares closed at $3.16 per share.

Those who purchased shares of Marrone Bio Innovations Inc (NASDAQ:MBII) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com